ArticleJournal of the Endocrine Society2025
Predictors of Initial Response of Thyroid Nodules Treated With RFA, a Multi-Endocrinology Centers Experience From the United States.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- New gadgets for thyroid ablation-what's the promise?Gland surgery · 2026Article
- Radiofrequency ablation of papillary thyroid microcarcinoma.Frontiers in surgery · 2026Review
- Feasibility and Short-Term Outcomes of Radiofrequency Ablation for Low-Risk Papillary Thyroid Carcinoma in an Outpatient Endocrinology Setting in the USA.Clinical medicine insights. Endocrinology and diabetes · 2026Article
- Predictors of Initial Response of Thyroid Nodules Treated With RFA, a Multi-Endocrinology Centers Experience From the United States.Journal of the Endocrine Society · 2025Article
- Assessing the impact of malignant thyroid nodules on the efficacy of radiofrequency ablation: a single-center prospective study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Given the growing utilization of radiofrequency ablation in the management of benign thyroid nodules, the identification of factors predicting successful outcomes is increasingly relevant for optimizing patient selection. Objective: This study is looking for potential factors influencing volume reduction (VR) after RFA in benign thyroid nodules. Methods: This is a multicenter, retrospective study of 275 benign thyroid nodules in 240 patients who underwent treatment with radiofrequency ablation (RFA) between November 2018 and March 2022. Results: The study included 240 patients (82.2% women) with 275 benign nodules (191 nonfunctional). Median age was 50 years (interquartile range [IQR] 22.5). After a mean (SD) follow-up of 186.1 (138.7) days, most patients experienced a 50% or more reduction in nodule volume after RFA, with a median volume reduction percentage (VRP) of 63.5% (IQR 48.1%-75.16%), and median absolute volume reduction (AVR) of 6.54 mL (IQR 2.85-14.97). Factors that predict AVR post RFA are female sex, ethnicity, and larger nodule volume before RFA and inversely duration of ablation time. Factors that predict VRP post RFA are age, non-Hispanic ethnicity, American Thyroid Association category very low risk and low risk, higher energy, and pre-RFA thyrotropin level. In a subgroup analysis of autonomously functioning thyroid nodules (AFTNs), the strongest predictor for achieving a normal thyroid function test was the severity of hyperthyroidism before the procedure, with better performance in subclinical hyperthyroidism. Conclusion: Our study suggests that larger nodules may still have successful ablation with higher AVR. A longer time of ablation or higher energy delivered may indicate a less responsive thyroid nodule, hence lower AVR and VRP. In AFTN, severity of hyperthyroidism is the strongest predictor of achieving normal euthyroid state post RFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.